Abbott's formula settlement closes a chapter but not the reputational wound

Abbott Laboratories agreed to pay $384 million to resolve federal allegations that it sold contaminated infant formula, one of the most damaging product-safety scandals in the company's recent history.

The dollar figure is manageable for a company Abbott's size, but settling with the federal government is a different kind of admission than a civil lawsuit — it signals the government had enough to press the case, and that tends to linger in how the public thinks about a brand.

Novo Nordisk's rebrand looks like a company running from its own reputation

Novo Nordisk announced it is dropping 'Nordisk' from its name on the same day Morgan Stanley downgraded the stock, citing weak growth prospects, patent risks, and mounting competitive pressure in the obesity drug market.

When a company rebrands at the exact moment a major analyst cuts its rating, the optics of reinvention start to look like damage control, not strategy.

Eli Lilly is winning the oral weight-loss race faster than anyone expected

Lilly told investors at a Morgan Stanley healthcare conference that its Foundayo pill has already captured more than 30% of new U.S. patients choosing an oral weight-loss drug, cutting into the early lead Novo Nordisk built with its injectable Wegovy.

Oral pills remove one of the biggest friction points for patients who balk at weekly injections, so Lilly's oral format advantage could prove more durable than a headline number suggests.